stockrowWhat it does
IDEXX Laboratories is headquartered in Westbrook and develops, makes and distributes diagnostic products and provides services for companion-animal veterinary practices, livestock, poultry, dairy and water testing. It also sells point-of-care diagnostic products for human medical hospitals and clinics. [item1]
Its main business is Companion Animal Group, or CAG. For a veterinary practice, that can mean instruments used inside the clinic to test blood, urine and other samples; single-use rapid tests; and samples sent to an IDEXX reference laboratory for more extensive testing and specialist consultation. The company connects results from its instruments, laboratories and imaging systems through software such as VetConnect PLUS, so veterinarians can view and share a patient’s diagnostic history. [item1]
CAG also includes practice-management software for electronic health records, scheduling, communications, billing and inventory; workflow tools; payments and client-engagement services; digital imaging systems; and telemedicine consultations. Its Water segment supplies tests and equipment that detect microbiological contaminants in drinking water, wastewater, recreational water, bottled water and production-process water. Its Livestock, Poultry and Dairy segment supplies tests used to manage animal health, support herd screening and detect antibiotic residues in milk. [item1]
The company operates through Companion Animal Group, Water and Livestock, Poultry and Dairy reportable segments. Human medical diagnostics and an out-licensing arrangement are included in Other. [item1]
How it makes money
IDEXX sells both capital equipment and recurring products and services. A veterinary clinic generally buys an analyzer once during its product life cycle, but then repeatedly buys the compatible consumables used to run tests. The company also places some instruments through arrangements in which customers commit for multiple years to buy recurring products and services. [item7]
Recurring CAG diagnostic revenue includes IDEXX VetLab consumables, SNAP rapid assay kits, reference-laboratory and consulting services, instrument maintenance agreements and accessories. Reference laboratories earn revenue when practices submit samples for testing, while software offerings such as Animana, ezyVet and IDEXX Neo use subscriptions. Imaging placements can also generate recurring maintenance and IDEXX Web PACS subscription revenue. [item7]
The CAG portfolio combines point-of-care testing, outside laboratory services, software and imaging. Water revenue comes from microbiological water tests, instruments, consumables, parts and accessories. LPD revenue comes from livestock and poultry diagnostic tests, herd-health services, pregnancy tests and dairy-residue tests. The Other segment sells human point-of-care analyzers and associated consumables. [item1]
Consumables, rapid assays, laboratory services and software subscriptions are bought repeatedly as tests are run or services are used. Instrument placements are non-recurring, and the mix of recurring versus instrument revenue affects gross margins because the company states that its recurring diagnostic products have higher gross margins than instrument sales. [item7]
Management said on the Q2 2026 call that inVue Dx consumable revenue was within a range of $3,500.00 to $5,500.00 per instrument. [call_qa; fact_f26847e8]
Customers and how it sells
CAG customers are veterinarians, independent veterinary clinics and corporate veterinary groups. Veterinary practices use in-clinic instruments, rapid assays, reference-laboratory services, software, imaging and telemedicine. The Water business sells to government laboratories, water utilities and private certified laboratories, as well as users testing water in production processes. LPD customers include government and private laboratories, livestock veterinarians, producers and processors. Human medical products are used by hospitals and clinics. [item1]
IDEXX sells and services products worldwide through its marketing, customer-service, sales and technical-service groups, as well as independent distributors and resellers. It sells companion-animal diagnostic products directly to U.S. veterinarians. Outside the U.S., it uses a direct sales force and, in certain countries, distributors and other resellers. Reference-laboratory services are generally sold worldwide through the direct sales force. [item1]
The company has a sales presence in the U.S., Africa, Asia Pacific, Canada, Europe and Latin America. Its reference-laboratory network serves customers in the U.S., Europe, Canada, Australia, Japan, New Zealand, South Africa and South Korea. Water and LPD products are primarily sold directly in the U.S. and Canada, with direct sales and selected distributors elsewhere. [item1]
Management said on the Q2 2026 call that 40.0% of inVue Dx placements were outside the U.S. [call_qa; fact_73703d8a]
Suppliers and costs
IDEXX manufactures some products itself, while certain instruments are made by third parties. It depends on third parties and direct suppliers for important components, raw materials and consumables; some are sole- or single-source suppliers. These include certain Catalyst consumables, ProCyte Dx analyzers and consumables, inVue Dx cytology consumables, SediVue Dx products, diagnostic imaging systems, and components for SNAP, dairy, livestock, poultry and water products. [item1]
Ortho-Clinical Diagnostics, Inc. supplies certain Catalyst chemistry slides under supply agreements. IDEXX must purchase all requirements for its current menu of those slides from Ortho when Ortho can supply them. Pricing is based on purchase volumes plus a fixed annual inflationary adjustment. [item1]
The company seeks to address sole- and single-source exposure by identifying alternatives, developing in-house capability, using manufacturing-information escrow arrangements for some products and maintaining safety stock. Its costs include employee compensation and benefits, inventory and supplies, research and development, capital expenditures, rents, occupancy charges, interest, taxes and acquisitions. [item1; item7]
- Revenue$4.3B
- Cost of revenue−$1.6B
- Research and development−$251.2M
- Selling, general and administrative−$1.0B
- Operating income$1.4B
Competitive position
IDEXX faces competition across companion-animal diagnostics, reference laboratories, veterinary software, diagnostic imaging, water testing, livestock testing and dairy testing. In North American companion-animal diagnostics, named competitors include Mars, Incorporated brands Antech Diagnostics and Heska, and Zoetis Inc., including Abaxis. Internationally, competitors also include scil animal care, Antech-Asia Veterinary Diagnostics, Fujifilm Holdings Corporation, Arkray, Inc., Mindray and BioNote, Inc. [item1]
In Water, LPD and dairy testing, competitors include Neogen Corporation, Charm Sciences, Inc., BioChek, Innovative Diagnostics and Thermo Fisher Scientific Inc. Covetrus, Inc. is the largest North American and U.K. competitor in veterinary software, while Sound-Eklin, Antech Diagnostics, FUJIFILM and Heska compete in diagnostic imaging. [item1]
IDEXX competes on ease of use, speed, diagnostic accuracy, product quality, test-menu breadth, technology integration, workflow, information management, service, sales channels and pricing relative to value. It uses patents, copyrights, trademarks, trade secrets and licensed technologies, but does not consider any individual intellectual-property right material to the business as a whole. [item1]
Our reading: Integration across in-clinic instruments, reference laboratories, imaging and practice software is a meaningful moat source because it puts diagnostic information and workflows in connected systems used by veterinary practices. [item1; item7]
Our reading: Recurring consumables, tests, laboratory services and subscriptions support customer continuity, but competitors offer products and services in each of these areas. [item1; item7]
Our reading: Intellectual property contributes to differentiation, but it is a limited standalone moat because IDEXX does not view any individual patent, copyright, trademark, trade secret or license as material and acknowledges intense competition. [item1; item1a]
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Antech Diagnostics | Companion-animal diagnostics and imaging | High |
| Heska | Companion-animal diagnostics and imaging | High |
| Zoetis Inc. | Companion-animal diagnostics internationally and North America | High |
| Covetrus, Inc. | Veterinary software in North America and U.K. | High |
| Thermo Fisher Scientific Inc. | Water, livestock, poultry and dairy testing | Medium |
| Neogen Corporation | Water, livestock, poultry and dairy testing | Medium |
| Fujifilm Holdings Corporation | International companion-animal diagnostics | Medium |
| Sound-Eklin | Veterinary diagnostic imaging systems | Medium |
Growth opportunities
IDEXX seeks to expand CAG recurring diagnostic revenue by increasing testing at existing customers, winning new customers, retaining customers and introducing new offerings. It aims to increase both the number of patient samples tested and the number of tests run per sample. The company also invests in field sales, laboratory capacity, software, information technology and diagnostic menu additions. [item7]
Management said on the Q2 2026 call that only around one in 10 U.S. wellness visits include blood work, and that blood-work penetration outside the U.S. is around one-third or less in most countries. Management identified wellness testing, international placements and utilization as areas for further diagnostic adoption. [call_qa; fact_42db198c; fact_518d9312]
Management said on the Q2 2026 call that IDEXX had placed 2,700 inVue Dx instruments in the first half of FY2026 and anticipated 5,500 placements for FY2026. It also said 9,000 instruments had been placed since launch. Management said consumable revenue was within $3,500.00 to $5,500.00 per instrument. [call_qa; fact_0bdb6be3; fact_18b17421; fact_b2ddbac9; fact_f26847e8]
The company sizes the current fine-needle-aspirate activity at 12,000,000 procedures and states that 90% or more of masses are not investigated. It has described the global manual cytology opportunity as 100,000,000 to 150,000,000 procedures. [fact_32833b4e; fact_bb649dd2]
Management said on the Q2 2026 call that Cancer Dx was drawing volume from practices using a competitive laboratory. The company had more than 7,500 practices ordering Cancer Dx since launch. [call_qa; fact_89876415; fact_d7e14ccc]
- $3.2BFY2021
- $3.4BFY2022
- $3.7BFY2023
- $3.9BFY2024
- $4.3BFY2025
- $4.7BFY2026 guidance
Structural risks
-
Companion-animal healthcare is highly competitive, and the company anticipates competition from existing companies and new entrants. Its future performance depends on introducing differentiated diagnostics, services and software while managing global growth and expansion. [item1a]
-
The business depends on third-party suppliers for components, raw materials, some manufactured products, cloud infrastructure, package delivery and other services. Sole- or single-source arrangements could disrupt product supply if suppliers cannot meet requirements or agreements end. [item1; item1a]
-
Many rapid assay, livestock, poultry, water and dairy products use biological materials. The company states that biologic products are complex and difficult to manufacture, which can constrain its ability to supply customers. [item1a]
-
Products and services are subject to U.S. and foreign rules covering approvals, registration, manufacturing, import and export, distribution, marketing, labeling, quality, storage, disposal and data. New or evolving requirements can delay or limit sales. [item1]
-
The company relies on its own and third-party information systems for web-based products, orders, shipments, inventory, records and confidential information. Disruption, a cybersecurity breach or another incident could affect these functions. [item1a]
-
International operations expose the company to currency movements, geopolitical conditions, macroeconomic weakness, trade restrictions, logistics disruptions and local regulation. Factors outside its control can disrupt operations, suppliers and customers. [item1a]
Bottom line
Our reading
Our reading: IDEXX is a diagnostics and practice-workflow business centered on veterinary customers, with instruments creating follow-on demand for consumables, laboratory testing, maintenance and software. [item1; item7]
Our reading: Its operating model combines direct customer relationships, an international laboratory network and connected information systems, while Water and LPD broaden the customer base beyond companion animals. [item1]
Our reading: Competition, supplier concentration, product regulation and dependence on veterinary testing demand remain material constraints on this model. [item1; item1a]